CHD+CKD
Conditions
Interventions
Healthy control group(Exploration cohort):None
Simple CHD group(Exploration cohort) :None
CHD + CKD group(Verification cohort):None
Isolated CKD group(Verification cohort):None
Healthy control group(Verification cohort):None
CHD + CKD group(Exploration cohort):None
Isolated CHD group(Exploration cohort ):None
Isolated CHD group(Verification queue):None
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. This study plans to include four groups of patients aged 18-85 years (CHD with CKD, CHD only, CKD only, and healthy controls, totaling 144 cases, with 24 cases in the discovery group and 120 cases in the validation group), who have signed informed consent. 2. CHD-related group: Patients meeting the diagnosis of coronary heart disease (history of PCI/CABG/myocardial infarction, or coronary angiography/CTA confirming >=50% stenosis, or stable angina with imaging confirming coronary atherosclerosis). 3. CKD-related group: CKD stages 3-5 (eGFR =3 months) and/or receiving maintenance dialysis; or with a clear history of CKD and meeting KDIGO staging criteria. 4. Healthy controls: No CHD, no CKD, and recent medical examinations show no active infection or inflammatory disease. 5. Able to provide qualified blood samples and meet the PBMC processing time requirements. Note: CHD CKD group must meet inclusion criteria 1, 2, 5 CHD-only group must meet inclusion criteria 1, 2, 5 CKD-only group must meet inclusion criteria 1, 3, 5 Healthy control group must meet inclusion criteria 1, 4, 5
Exclusion criteria
Exclusion criteria: 1.Acute infections or fevers in the past 4 weeks; 2.Active autoimmune diseases, malignant tumors or those undergoing chemotherapy/ radiotherapy; 3.Recent major surgeries, severe traumas or acute cardiovascular events within the past 4 weeks; 4.Long-term immunosuppressive therapy (such as systemic glucocorticoids with a prednisone equivalent of >10 mg/day administered continuously for >2 weeks, or biologics/immunosuppressants); 5.Pregnancy or lactation period; 6.Other circumstances that the researchers considered unsuitable for inclusion in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of iMLM subpopulations in PBMC and their transcriptional characteristics / key pathway activities;Independent association strength of iMLM and inflammatory factors such as IL-1ß/IL-6 with adverse cardiorenal outcomes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Organ-on-chip readouts (permeability, adhesion, SMC phenotype, microthrombus/calcification markers);Plaque burden, inflammation, and cardiorenal structural and functional indicators in animal models; | — |
Countries
China
Contacts
Public ContactGao Yuanfeng
China-Japan Friendship Hospital
Outcome results
None listed